AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors
AKT-mTORC1 重新激活是 PTEN 基因缺失的乳腺癌中 PI3Kβ/AKT 抑制剂产生耐药性的主要驱动因素，可通过与 Mcl-1 抑制剂联合使用来克服
期刊:Oncogene
影响因子:6.9
doi:10.1038/s41388-022-02482-9
Shanade Dunn, Cath Eberlein, Jason Yu, Albert Gris-Oliver, Swee Hoe Ong, Urs Yelland, Natalie Cureton, Anna Staniszewska, Robert McEwen, Millie Fox, James Pilling, Philip Hopcroft, Elizabeth A Coker, Patricia Jaaks, Mathew J Garnett, Beverley Isherwood, Violeta Serra, Barry R Davies, Simon T Barry,
信号转导
肿瘤
乳腺癌
IP
WB
PI3K/Akt
mTOR
Human
P85B
